<?xml version="1.0" encoding="UTF-8"?>
<p>Our group has focussed on the development of HDAC inhibitors with various core scaffolds including indole
 <xref rid="CIT0021" ref-type="bibr">
  <sup>21â€“24</sup>
 </xref>, indoline
 <xref rid="CIT0025" ref-type="bibr">
  <sup>25</sup>
 </xref>
 <sup>,</sup>
 <xref rid="CIT0026" ref-type="bibr">
  <sup>26</sup>
 </xref>, and quinoline
 <xref rid="CIT0027" ref-type="bibr">
  <sup>27</sup>
 </xref>
 <sup>,</sup>
 <xref rid="CIT0028" ref-type="bibr">
  <sup>28</sup>
 </xref>. In a study related of quinoline-derived compounds, we found that 2-(phenylsulfonyl)quinoline-
 <italic>N</italic>-hydroxyacrylamides (
 <bold>6</bold>) exhibit potent pan-HDAC inhibitory and antiproliferative activity
 <xref rid="CIT0027" ref-type="bibr">
  <sup>27</sup>
 </xref>.
</p>
